Idenix Reports Mixed Hepatitis Research
Posted on: Friday, 13 April 2007, 09:00 CDT
Idenix Pharmaceuticals has reported mixed data from two mid-stage studies of its hepatitis C treatment valopicitabine in combination with pegylated interferon alfa-2a.
The drug produced disappointing results in one study but in another ongoing a study the data was more encouraging.
One study showed that when valopicitabine was combined with pegylated interferon the therapy worked no better then the current standard of care ribavirin. Of patients treated with valopicitabine in combination with pegylated interferon, none achieved a sustained virologic response, compared to one patient retreated with pegylated interferon and ribavirin.
The primary endpoint of the other study was sustained virologic response, defined as maintained viral clearance six months after treatment is stopped. At the end of the treatment period, 53% of patients treated with 200 mg/day valopicitabine plus pegylated interferon achieved undetectable HCV levels.
Idenix said that the treatment still holds promise. The company believes the data warrant further studies to assess if the addition of ribavirin and potentially another investigational agent to this treatment regimen could offer some of the patients a viable treatment option.
Source: Datamonitor
Related Articles
- Local Neurosurgeon Co-Authors National Treatment Guidelines for Brain Tumor Patients
- Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
- Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
- Sucampo Pharmaceuticals Initiates Phase 2 Trial of Cobiprostone for the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
- New Non-Invasive Treatment Option for Lung Cancer Patients Offered By CyberKnife Center of Miami
- Somaxon Pharmaceuticals to Announce Results of Phase 3 Clinical Trial of SILENOR(TM) for the Treatment of Insomnia in Elderly Patients and Host Conference Call
- Cyberonics Announces Closure of Investigational Device Exemption (IDE) for Treatment-Resistant Depression (TRD), Lifetime Reimbursement Guarantee for All TRD IDE Study Patients and $15 Million TRD Indigent Care Program
- Clinical Characteristics and Treatment Responses of Tuberculosis in Patients With Malignancy Receiving Anticancer Chemotherapy*
- CORRECTING AND REPLACING Study of Claims Data Finds REMICADE Dosing Remains Stable With Maintenance Therapy Over Two Year Period
- Study of Claims Data Finds REMICADE Dosing Remains Stable With Maintenace Therapy Over Two Year Period
 |
 |
User Comments (0)
RSS Feeds